Belgium· BE-AMP-SAM660369-00
Lunsumio 1 mg
A mosunetuzumab product containing mosunetuzumab, registered in Belgium by Roche Registration. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Mosunetuzumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX25 (mosunetuzumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Mosunetuzumab · ATC L01FX25
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Mosunetuzumab
- Manufacturer
- Roche Registration
- Country
- Belgium (BE)
- ATC code
- L01FX25
- ATC class
- Mosunetuzumab
- Defined daily dose
- 1.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb4604542
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mosunetuzumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandLunsumioOrifarm Oy
- CzechiaLUNSUMIORoche Registration GmbH, Grenzach-Wyhlen
- IrelandLunsumio 1 mg concentrate for solution for infusionRoche Registration GmbH
- IcelandLunsumioRoche Registration GmbH*
- PolandLunsumioRoche Registration GmbH
- SwedenLunsumio 1 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
- United StatesLunsumioGenentech, Inc.
- SpainLUNSUMIO 1 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lunsumio
- Liechtenstein · Lunsumio
- Norway · Lunsumio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2f8c8cd6-7729-42b6-83fe-3a0f535d9551 GET /v1/drugs/2f8c8cd6-7729-42b6-83fe-3a0f535d9551?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Lunsumio 1 mg",
"name_fr": "Lunsumio 1 mg",
"name_nl": "Lunsumio 1 mg",
"amp_code": "SAM660369-00",
"strengths": [
"1.0000",
"1.0000"
],
"pack_count": 1,
"substances": [
"Mosunetuzumab",
"Sucrose",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Mosunetuzumab",
"authorisation_numbers": [
"EU/1/22/1649/001"
]
}See everything about mosunetuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.